GANGAPHARM
Ganga Pharmaceuticals financials
- Market cap
- ₹7 Cr
Quarterly results
Q4 FY26: revenue up 2.8%, net profit up 166.7% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | 1 | 1 −3% | 1 +8% | 1 +4% | 1 +3% |
| EBITDA | 0 | -0 | 0 | 0 | -0 −257% | 0 +100% | -0 −140% | 0 +600% |
| Net profit | 0 | 0 | 0 | 0 | 0 −33% | 0 +500% | 0 +0% | 0 +167% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −14.4% 1Y
1Y: ₹14.6 on 3 Sept 2025 → ₹12.5. High ₹14.6 (3 Sept 2025), low ₹11.68 (20 Nov 2025).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr | ₹6 Cr | ₹6 Cr |
| Reserves | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Borrowings | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Total liabilities | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr |
| Fixed assets | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹10 Cr | ₹9 Cr |
| Total assets | ₹8 Cr | ₹8 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, promoters trimmed −5.11 pp while the public added +5.11 pp.
- Promoters
- 50.9%
- Public
- 49.1%
Since Mar 2025
- Promoters −5.11 pp
- Public +5.11 pp
How it drifted, 12 quarters
Over this window promoters fell from 66.7% to 50.9% — −15.8 pp.
Ownership split by quarter, oldest first. Sep '21: Promoters 66.7%, Public 33.3%.Dec '21: Promoters 66.7%, Public 33.3%.Mar '22: Promoters 66.7%, Public 33.3%.Jun '22: Promoters 66.7%, Public 33.3%.Sep '22: Promoters 66.7%, Public 33.3%.Mar '23: Promoters 66.7%, Public 33.3%.Sep '23: Promoters 66.7%, Public 33.3%.Mar '24: Promoters 56.0%, Public 44.0%.Sep '24: Promoters 56.0%, Public 44.0%.Mar '25: Promoters 56.0%, Public 44.0%.Sep '25: Promoters 50.9%, Public 49.1%.Mar '26: Promoters 50.9%, Public 49.1%.
Who is on the register
Named in the Mar 2026 filing
Every holder of Ganga Pharmaceuticals Limited above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Sharma Bharat B | 24.64% | unchanged |
| Srijna Sharma | 7.48% | unchanged |
| Bhavesh Dhirajlal Tanna | 6.61% | unchanged |
| Lenus Finvest Private Limited | 6.34% | unchanged |
| Plutus Capital Management Llp . | 6.34% | unchanged |
| Anagh Bharat Sharma | 6.09% | unchanged |
| Brijmohan Sharma Huf | 5.91% | unchanged |
| Prakash Dhirajlal Tanna | 5.50% | unchanged |
| Bharat Brijmohan Sharma Huf Sharma | 3.21% | unchanged |
| Niranjan Kumar Goel | 2.44% | unchanged |
| Usha Shukla | 1.61% | unchanged |
| Amit Shukla | 1.29% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Ganga Pharmaceuticals Limited
Guides on how to read this kind of business and the numbers that matter.